Prelude Therapeutics Inc Stock
Prelude Therapeutics Inc Stock price
Key metrics
| Market capitalization | $105.65m |
| Enterprise Value | $-55.99m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | 0.53 |
| P/B ratio (TTM) P/B ratio | 0.58 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-142.27m |
| Free Cash Flow (TTM) Free Cash Flow | $-106.48m |
| Cash position | $179.84m |
Is Prelude Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,907 stocks worldwide.
Prelude Therapeutics Inc Stock Analysis
Analyst Opinions
5 Analysts have issued a Prelude Therapeutics Inc forecast:
Analyst Opinions
5 Analysts have issued a Prelude Therapeutics Inc forecast:
Financial data from Prelude Therapeutics Inc
| Jun '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -1.49 -1.49 |
50%
50%
|
|
| EBITDA | -141 -141 |
15%
15%
|
EBIT (Operating Income) EBIT | -142 -142 |
14%
14%
|
| Net Profit | -130 -130 |
11%
11%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Prelude Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Prelude Therapeutics Inc Stock News
Company Profile
Prelude Therapeutics, Inc. operates as a cancer drug discovery company. It focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Gopi Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.
| Head office | United States |
| CEO | Krishna Vaddi |
| Employees | 128 |
| Founded | 2016 |
| Website | www.preludetx.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
